Patents by Inventor Akihiko Tsuruoka
Akihiko Tsuruoka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190111043Abstract: The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: December 19, 2018Publication date: April 18, 2019Applicants: NATIONAL CANCER CENTER, Eisai R&D Management Co., Ltd.Inventors: Tatsuhiro SHIBATA, Yasuhito ARAI, Kenichi NOMOTO, Tomio NAKAMURA, Akihiko TSURUOKA, Saori MIYANO
-
Publication number: 20190000829Abstract: A therapeutic agent for biliary tract cancer comprising 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide or a pharmacologically acceptable salt thereof is provided.Type: ApplicationFiled: August 17, 2016Publication date: January 3, 2019Applicant: Eisai R&D Management Co., Ltd.Inventors: Junji Matsui, Masahiro Matsuki, Akihiko Tsuruoka, Toshiyuki Tamai, Ryo Nakajima, Takuya Suzuki
-
Publication number: 20180015079Abstract: The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: March 23, 2016Publication date: January 18, 2018Inventors: Tatsuhiro SHIBATA, Yasuhito ARAI, Kenichi NOMOTO, Tomio NAKAMURA, Akihiko TSURUOKA, Saori MIYANO
-
Patent number: 8865737Abstract: The present invention relates to a therapeutic agent represented by the General formula (I), or a pharmacologically acceptable salt thereof, or a solvate of the compound or the salt thereof: The therapeutic agent comprises a substance having the activity of inhibiting kinase activity of fibroblast growth factor receptor 2 (“FGFR2”). The therapeutic agent can be used for treating undifferentiated gastric cancer, and can also be used to treat organisms comprising a cell overexpressing FGFR2 or a cell expressing mutant FGFR2, or both. The present invention further relates to a pharmaceutical composition comprising an FGFR2 inhibitory and methods of treatment therewith. The present invention also relates to a method for predicting the effect of an FGFR2 inhibitory substance on a patient.Type: GrantFiled: August 27, 2007Date of Patent: October 21, 2014Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuji Yamamoto, Tomohiro Matsushima, Akihiko Tsuruoka, Hiroshi Obaishi, Takayuki Nakagawa
-
Patent number: 7994159Abstract: It was discovered that a compound represented by the general formula (I) shows strong c-Kit kinase inhibitory activity, and it inhibits proliferation of c-Kit kinase activated-cancer cells in vitro and in vivo. A novel anticancer agent showing c-Kit kinase inhibitory activity was discovered. The general formula (I): (wherein R1 represents methyl etc., R2 represents cyano etc., R3 represents hydrogen etc., R4 represents hydrogen etc.).Type: GrantFiled: March 10, 2004Date of Patent: August 9, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuji Yamamoto, Tatsuo Watanabe, Masayuki Okada, Akihiko Tsuruoka
-
Publication number: 20110118470Abstract: Compounds represented by the following general formula: wherein Ag is an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xg is —O—, —S—, etc.; Yg is an optionally substituted C6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tg1 is a group represented by the following general formula: (wherein Eg is a single bond or —N(Rg2)—), Rg1 and Rg2 each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, etc. and Zg represents a C1-8 alkyl group, a C3-8 alicyclic hydrocarbon group, a C6-14 aryl group, etc.), salts thereof or hydrates of the foregoing.Type: ApplicationFiled: January 7, 2011Publication date: May 19, 2011Inventors: Yasuhiro FUNAHASHI, Akihiko Tsuruoka, Masayuki Matsukura, Toru Haneda, Yoshio Fukuda, Junichi Kamata, Keiko Takahashi, Tomohiro Matsushima, Kazuki Miyazaki, Ken-ichi Nomoto, Tatsuo Watanabe, Hiroshi Obaishi, Atsumi Yamaguchi, Sachi Suzuki, Katsuji Nakamura, Fusayo Mimura, Yuji Yamamoto, Junji Matsui, Kenji Matsui, Takako Yoshiba, Yasuyuki Suzuki, Itaru Arimoto
-
Patent number: 7834049Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.Type: GrantFiled: April 4, 2005Date of Patent: November 16, 2010Assignee: Eisai R&D Management Co., Ltd.Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
-
Publication number: 20100267754Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.Type: ApplicationFiled: June 10, 2010Publication date: October 21, 2010Inventors: Toshiaki WAKABAYASHI, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
-
Publication number: 20100197911Abstract: Compounds represented by the following general formula: [wherein Ag is an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xg is —O—, —S—, etc.; Yg is an optionally substituted C6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tg1 is a group represented by the following general formula: (wherein Eg is a single bond or —N(Rg2)—, Rg1 and Rg2 each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, etc. and Zg represents a C1-8 alkyl group, a C3-8 alicyclic hydrocarbon group, a C6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.Type: ApplicationFiled: October 2, 2008Publication date: August 5, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Yasuhiro Funahashi, Akihiko Tsuruoka, Masayuki Matsukura, Toru Haneda, Yoshio Fukuda, Junichi Kamata, Keiko Takahashi, Tomohiro Matsushima, Kazuki Miyazaki, Ken-ichi Nomoto, Tatsuo Watanabe, Hiroshi Obaishi, Atsumi Yamaguchi, Sachi Suzuki, Katsuji Nakamura, Fusayo Mimura, Yuji Yamamoto, Junji Matsui, Kenji Matsui, Takako Yoshiba, Yasuyuki Suzuki, Itaru Arimoto
-
Patent number: 7612092Abstract: Compounds represented by the following general formula: [wherein Ag is an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xg is —O—, —S—, etc.; Yg is an optionally substituted C6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tg1 is a group represented by the following general formula: (wherein Eg is a single bond or —N(Rg2)—, Rg1 and Rg2 each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, etc. and Zg represents a C1-8 alkyl group, a C3-8 alicyclic hydrocarbon group, a C6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.Type: GrantFiled: December 2, 2005Date of Patent: November 3, 2009Assignee: Eisai R & D Management Co., Ltd.Inventors: Yasuhiro Funahashi, Akihiko Tsuruoka, Masayuki Matsukura, Toru Haneda, Yoshio Fukuda, Junichi Kamata, Keiko Takahashi, Tomohiro Matsushima, Kazuki Miyazaki, Ken-ichi Nomoto, Tatsuo Watanabe, Hiroshi Obaishi, Atsumi Yamaguchi, Sachi Suzuki, Katsuji Nakamura, Fusayo Mimura, Yuji Yamamoto, Junji Matsui
-
Publication number: 20090264464Abstract: The present invention relates to a therapeutic agent represented by the General formula (I), or a pharmacologically acceptable salt thereof, or a solvate of the compound or the salt thereof: The therapeutic agent comprises a substance having the activity of inhibiting kinase activity of fibroblast growth factor receptor 2 (“FGFR2”). The therapeutic agent can be used for treating undifferentiated gastric cancer, and can also be used to treat organisms comprising a cell overexpressing FGFR2 or a cell expressing mutant FGFR2, or both. The present invention further relates to a pharmaceutical composition comprising an FGFR2 inhibitory and methods of treatment therewith. The present invention also relates to a method for predicting the effect of an FGFR2 inhibitory substance on a patient.Type: ApplicationFiled: August 27, 2007Publication date: October 22, 2009Applicant: Eisai R & D Management Co., Ltd.Inventors: Yuji Yamamoto, Tomohiro Matsushima, Akihiko Tsuruoka, Hiroshi Obaishi, Takayuki Nakagawa
-
Patent number: 7550483Abstract: An amorphous form of a salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.Type: GrantFiled: June 22, 2006Date of Patent: June 23, 2009Assignee: Eisai R&D Management Co., Ltd.Inventors: Takahisa Sakaguchi, Akihiko Tsuruoka
-
Patent number: 7468380Abstract: A compound represented by the general formula: wherein X1 represents a nitrogen atom or a group represented by the formula —CR10?; X2 represents a nitrogen atom or a group represented by the formula —CR11?; Y represents an oxygen atom or the like; R1 represents a C1-6 alkoxy group, an optionally substituted C6-10 aryloxy group, a group represented by the formula —NR12aR12b or the like; R2 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like; R3, R4, R5, R6, R7, R8, R10 and R11 each independently represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or the like; R9 represents a group represented by the formula —NR16aR16b or the like; and R12a, R12b, R16a and R16b each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, a salt thereof, or a hydrate of the foregoing.Type: GrantFiled: August 18, 2006Date of Patent: December 23, 2008Assignee: Eisai R&D Management Co., Ltd.Inventors: Akihiko Tsuruoka, Tomohiro Matsushima, Masayuki Matsukura, Kazuki Miyazaki, Keiko Takahashi, Junichi Kamata, Yoshio Fukuda
-
Patent number: 7253286Abstract: Compounds represented by the following general formula: [wherein Ag is an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xg is —O—, —S—, etc.; Yg is an optionally substituted C6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tg1 is a group represented by the following general formula: (wherein Eg is a single bond or —N(Rg2)—, Rg1 and Rg2 each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, etc. and Zg represents a C1-8 alkyl group, a C3-8 alicyclic hydrocarbon group, a C6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.Type: GrantFiled: April 18, 2003Date of Patent: August 7, 2007Assignee: Eisai Co., LtdInventors: Yasuhiro Funahashi, Akihiko Tsuruoka, Masayuki Matsukura, Toru Haneda, Yoshio Fukuda, Junichi Kamata, Keiko Takahashi, Tomohiro Matsushima, Kazuki Miyazaki, Ken-ichi Nomoto, Tatsuo Watanabe, Hiroshi Obaishi, Atsumi Yamaguchi, Sachi Suzuki, Katsuji Nakamura, Fusayo Mimura, Yuji Yamamoto, Junji Matsui, Kenji Matsui, Takako Yoshiba, Yasuyuki Suzuki, Itaru Arimoto
-
Publication number: 20070004764Abstract: A compound represented by the general formula: wherein X1 represents a nitrogen atom or a group represented by the formula —CR10?; X2 represents a nitrogen atom or a group represented by the formula —CR11?; Y represents an oxygen atom or the like; R1 represents a C1-6 alkoxy group, an optionally substituted C6-10 aryloxy group, a group represented by the formula —NR12aR12b or the like; R2 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like; R3, R4, R5, R6, R7, R8, R10 and R11 each independently represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or the like; R9 represents a group represented by the formula —NR16aR16b or the like; and R12a, R12b, R16a and R16b each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, a salt thereof, or a hydrate of the foregoing.Type: ApplicationFiled: August 18, 2006Publication date: January 4, 2007Inventors: Akihiko Tsuruoka, Tomohiro Matsushima, Masayuki Matsukura, Kazuki Miyazaki, Keiko Takahashi, Junichi Kamata, Yoshio Fukuda
-
Publication number: 20070004773Abstract: An amorphous form of a salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.Type: ApplicationFiled: June 22, 2006Publication date: January 4, 2007Applicant: Eisai R&D Management Co., Ltd.Inventors: Takahisa Sakaguchi, Akihiko Tsuruoka
-
Publication number: 20060247259Abstract: Compounds represented by the following general formula: [wherein Ag is an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xg is —O—, —S—, etc.; Yg is an optionally substituted C6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tg1 is a group represented by the following general formula: (wherein Eg is a single bond or —N(Rg2)—, Rg1 and Rg2 each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, etc. and Zg represents a C1-8 alkyl group, a C3-8 alicyclic hydrocarbon group, a C6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.Type: ApplicationFiled: December 2, 2005Publication date: November 2, 2006Inventors: Yasuhiro Funahashi, Akihiko Tsuruoka, Masayuki Matsukura, Toru Haneda, Yoshio Fukuda, Junichi Kamata, Keiko Takahashi, Tomohiro Matsushima, Kazuki Miyazaki, Ken-ichi Nomoto, Tatsuo Watanabe, Hiroshi Obaishi, Atsumi Yamaguchi, Sachi Suzuki, Katsuji Nakamura, Fusayo Mimura, Yuji Yamamoto, Junji Matsui, Kenji Matsui, Takako Yoshiba, Yasuyuki Suzuki, Itaru Arimoto
-
Patent number: 7109219Abstract: A compound represented by the general formula: wherein X1 represents a nitrogen atom or a group represented by the formula —CR10?; X2 represents a nitrogen atom or a group represented by the formula —CR11?; Y represents an oxygen atom or the like; R1 represents a C1-6 alkoxy group, an optionally substituted C6-10 aryloxy group, a group represented by the formula —NR12aR12b or the like; R2 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like; R3, R4, R5, R6, R7, R8, R10 and R11 each independently represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or the like; R9 represents a group represented by the formula —NR12aR12b or the like; and R12a and R12b each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, a salt thereof, or a hydrate of the foregoing.Type: GrantFiled: August 29, 2003Date of Patent: September 19, 2006Assignee: Eisai Co., Ltd.Inventors: Akihiko Tsuruoka, Tomohiro Matsushima, Masayuki Matsukura, Kazuki Miyazaki, Keiko Takahashi, Junichi Kamata, Yoshio Fukuda
-
Publication number: 20060160832Abstract: Compounds represented by the following general formula: [wherein Ag is an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xg is —O—, —S—, etc.; Yg is an optionally substituted C6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tg1 is a group represented by the following general formula: (wherein Eg is a single bond or —N(Rg2)—, Rg1 and Rg2 each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, etc. and Zg represents a C1-8 alkyl group, a C3-8 alicyclic hydrocarbon group, a C6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.Type: ApplicationFiled: February 3, 2006Publication date: July 20, 2006Inventors: Yosuhiro Funahashi, Akihiko Tsuruoka, Masayuki Matsukura, Toru Haneda, Yoshio Fukuda, Junichi Kamata, Keiko Takahashi, Tomohiro Matsushima, Kazuki Miyazaki, Ken-ichi Nomoto, Tatsuo Watanabe, Hiroshi Obaishi, Atsumi Yamaguchi, Sachi Suzuki, Katsuji Nakamura, Fusayo Mimura, Yuji Yamamoto, Junji Matsui, Kenji Matsui, Takako Yoshiba, Yasuyuki Suzuki, Itaru Arimoto
-
Publication number: 20060004029Abstract: A compound represented by the general formula: wherein X1 represents a nitrogen atom or a group represented by the formula —CR10?; X2 represents a nitrogen atom or a group represented by the formula —CR11?; Y represents an oxygen atom or the like; R1 represents a C1-6 alkoxy group, an optionally substituted C6-10 aryloxy group, a group represented by the formula —NR12aR12b or the like; R2 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like; R3, R4, R5, R6, R7, R8, R10 and R11 each independently represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or the like; R9 represents a group represented by the formula —NR16aR16b or the like; and R12a, R12b, R16a and R16b each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, a salt thereof, or a hydrate of the foregoing.Type: ApplicationFiled: August 28, 2003Publication date: January 5, 2006Inventors: Akihiko Tsuruoka, Tomohiro Matsushima, Masayuki Matasukura, Kazuki Miyazaki, Keiko Takahashi, Junichi Kamata, Yoshio Fukuda